ABBV
A little less AbbVie, a little more caution
Natural Investments LLC just pared back its AbbVie position by 27.1%, selling 10,548 shares and leaving it with 28,305 shares worth about $6.47 million. In portfolio terms, AbbVie still matters — it’s the fund’s 13th-largest holding and about 1.6% of assets — but the cut says the firm wanted to dial down exposure, not double down.
Why investors should care
This isn’t the kind of headline that sends the stock into orbit, but it does add to the vibe check around AbbVie. When one investor trims, fine. When you also see recent insider selling and a stock that’s already been under valuation and technical pressure, the market starts acting like it’s hearing storm warnings before the clouds fully roll in.
The dividend is doing its best impression of a life raft
AbbVie still has the kind of income story that makes dividend hunters swoon: a $1.73 quarterly payout, or $6.92 annualized, which works out to a roughly 3.4% yield. That’s real cash in your pocket while you wait for the market to decide whether the pharma giant is cheap or just annoyingly stubborn.
The pipeline keeps the drama going
The company also has some catalyst grease on the wheels, including strong Phase 2 data for ELAHERE and a licensing deal tied to pain assets that could be worth roughly $715 million to $745 million if everything lands. So yes, the stock may be getting side-eye from the market — but AbbVie still has enough moving pieces to keep investors from sleeping on it.
Big picture: AbbVie is in that classic mature-big-pharma zone where the dividend keeps the floor from collapsing, while pipeline news decides whether the ceiling gets higher.